The FDA on June 18, 2025, approved MONJUVI® with Lenalidomide and Rituximab for adults with relapsed or refractory Follicular Lymphoma (FL). MONJUVI® is a product of Incyte Corporation.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement
Advertisement
The FDA on June 18, 2025, approved MONJUVI® with Lenalidomide and Rituximab for adults with relapsed or refractory Follicular Lymphoma (FL). MONJUVI® is a product of Incyte Corporation.
Advertisement